For the month of: July 2013
|
Commission File Number: 001-35776
|
Form 20-F [ ]
|
Form 40-F [X]
|
Acasti Pharma Inc.
|
||
Date: July 16, 2013
|
By:
|
/s/ Henri Harland
|
Name:
|
Henri Harland
|
|
Title:
|
Chief Executive Officer
|
Exhibit
|
Description of Exhibit
|
99.1
|
Early Warning Report
|
1.
|
Name and address of the offeror
|
2.
|
The designation and number or principal amount of securities and Neptune’s security holding percentage in the class of securities of which Neptune acquired ownership or control in the transaction or occurrence giving rise to the obligation to file the news release, and whether it was ownership or control that was acquired in those circumstances.
|
3.
|
The designation and number or principal amount of securities and Neptune’s security holding percentage in the class of securities immediately after the transaction or occurrence giving rise to the obligation to file a news release.
|
4.
|
The designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities referred to in paragraph 3 over which:
|
(i)
|
Neptune, either alone or together with joint actors, has ownership and control,
|
(ii)
|
Neptune, either alone or together with joint actors, has ownership but control is held by other persons or companies other than Neptune or any joint actor,
|
(iii)
|
Neptune, either alone or together with joint actors, has exclusive or shared control but does not have ownership.
|
5.
|
The name of the market in which the transaction or occurrence that gave rise to the news release took place.
|
6.
|
The value, in Canadian dollars, of any consideration offered per security if Neptune acquired ownership of a security in the transaction or occurrence giving rise to the obligation to file a news release.
|
7.
|
The purpose of Neptune and any joint actors in effecting the transaction or occurrence that gave rise to the news release, including any future intention to acquire ownership of, or control over, additional securities of the reporting issuer.
|
8.
|
The general nature and the material terms of any agreement, other than lending arrangements, with respect to securities of the reporting issuer, entered into by Neptune, or any joint actor, and the issuer of the securities or any other entity in connection with the transaction or occurrence giving rise to the news release, including agreements with respect to the acquisition, holding, disposition or voting of any securities.
|
9.
|
The names of any joint actors in connection with the disclosure required by this form.
|
10.
|
In the case of a transaction or occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, the nature and value in Canadian dollars of the consideration paid by Neptune.
|
11.
|
If applicable, a description of any change in any material fact set out in a previous report by the entity under the early warning requirements or Part 4 of National Instrument 62-103 in respect of the reporting issuer’s securities.
|
12.
|
If applicable, a description of the exemption from securities legislation being relied on by Neptune and the facts supporting that reliance.
|
NEPTUNE TECHNOLOGIES &
BIORESSOURCES INC.
|
||
By:
|
/s/ André Godin
|
|
Name: André Godin
|
||
Title: Chief Financial Officer
|
||